Hematology
| 2 min read
Exelixis initiates Phase 3 pivotal trial (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab, versus nivolumab and ipilimumab, in previously untreated advanced renal cell carcinoma
| 3 min read
Merck's Keytruda racks up yet another FDA approval—this time as a combination with Inlyta for patients with renal cell carcinoma
| 3 min read
Balversa (erdafitinib) receives FDA approval for treatment of patients with advanced or metastatic urothelial carcinoma with certain FGFR genetic alterations
| 3 min read
MOR208 clinical trial results promising and drug is on fast track to FDA approval, company says
| 4 min read
Company aims to develop cancer immunotherapy candidate, which is a selective inhibitor of TGFβ1 activation
| 4 min read
A newly developed tumor model could offer better accuracy
| 2 min read
Preclinical data demonstrates the potential of QED Therapeutics’ infigratinib in multiple FGFR+ tumor types
| 4 min read
Three-pronged attack with targeted drugs can overcome drug resistance in bowel cancer
| 2 min read
Xynomic Pharmaceuticals to present at ASCO 2019 Annual Meeting; Xynomic sponsors EU investigator meeting for potentially pivotal kidney cancer trial
| 2 min read
Mogrify awarded $555,000 Innovate UK funding to accelerate regenerative cell therapies
| 3 min read
Catalyst Biosciences announces preclinical data on gene therapy candidate for hemophilia B
| 3 min read
GT Biopharma encouraged by clinical potential of triple-threat TriKE cells in cancer
